⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

November 24, 2003Journal of Neurology Neurosurgery & PsychiatryOpen Access

A post-marketing study on interferon 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients

View Full Paper

Ask AI

Bookmark

Share

Authors

CMC. MilaneseFondazione IRCCS Istituto Neurologico Carlo Besta

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

C. Milanese (2003) studied this question.

synapsesocial.com/papers/6a6b412e56128ae23fcb3c04 https://doi.org/10.1136/jnnp.74.12.1689

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

1A 6‐year clinical and MRI follow‐up study of patients with relapsing–remitting multiple sclerosis treated with Interferon‐beta2002 · 68 citations
2Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis1996 · 2,457 citations
3A prospective, open‐label treatment trial to compare the effect of IFN β‐1a (Avonex), IFNβ‐1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing‐remitting multiple sclerosis2001 · 52 citations